EpiVacCorona
phone-call sandwich
EpiVacCorona

EpiVacCorona

The EpiVacCorona vaccine was developed by the Vector State Scientific Center for Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
On January 1, 2021, it was released for public use and is actively used in the vaccination of the population against COVID-19.
The vaccine was registered on October 13, 2020. Registration certificate №ЛП-006504.


EpiVacCorona

EpiVacCorona

The EpiVacCorona vaccine does not contain live weakened viruses or genetic material from the COVID-19 virus. Clinical trials were conducted by 9 medical organizations in Moscow, the Moscow Region, Kazan, Tyumen and Kaliningrad on volunteers 18 years of age and older, as well as in the Novosibirsk Region (on volunteers over 60 years of age). In May 2021, the company received more than 100 requests for the vaccine from Turkmenistan, Belarus, Venezuela, India and Brazil, among other countries.


Vaccine

EpiVacCorona

Developer

Vector State Scientific Center for Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

Producer

  • Vector State Scientific Center for Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

  • Vector-BiAlgam JSC, Novosibirsk

  • Geropharm, Saint Petersburg

Status

Medical product registration certificate № LP-006504
EpiVacCorona underwent pre-clinical trials over the course of 4.5 months, followed by 3 stages of clinical trials.
Before starting clinical trials, the vaccine passed all preclinical efficacy and safety tests, involving experiments on various types of laboratory animals (including 2 types of primates).

Key information

What’s in the vaccine?

The vaccine contains peptide antigens, pieces of SARS-CoV-2 proteins that help the organism develop antibodies.


Vaccines developed and used in Russia